nach oben

Current Treatment Options in Neurology

Erschienen in:

01.04.2013 | CRITICAL CARE NEUROLOGY (KN SHETH, SECTION EDITOR)

Clinical Predictors and Management of Hemorrhagic Transformation

verfasst von: Raphaella E. Weiser, MD, Kevin N. Sheth, MD, FAHA

Erschienen in: Current Treatment Options in Neurology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Opinion statement

Hemorrhagic Transformation (HT) has been well recognized as a common cause of hemorrhage in ischemic stroke patients. Though this complication may occur independently, it has been particularly dreaded in the post rTPA patient and thus has been the focus for analysis of multiple thrombolytic trials. This review examines the effect of different clinical predictors for hemorrhagic transformation and summarizes pertinent clinical trials, with a focus on the rational for design of future studies. Although currently there are no official guidelines for the acute management of HT per se, based upon review of the literature regarding pertinent clinical predictors herein, an innovative approach for the acute management of the HT patient is proposed.

Terruso V, D'Amelio M, Di Benedetto N, et al. Frequency and determinants for hemorrhagic transformation of cerebral infarction. Neuroepidemiology. 2009;33:261–65.PubMed

Amarenco P, Hauw JJ, Gautier JC. Arterial pathology in cerebellar infarction. Stroke. 1990;21:1299–305.PubMed

Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke. 2008;39:2249–56.PubMed

Toni D, Fiorelli M, Bastianello S, et al. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology. 1996;46:341–45.PubMed

Dippel DW, Du Ry van Beest Holle M, Van Kooten F, Koudstaal PJ. The validity and reliability of signs of early infarction on CT in acute ischaemic stroke. Neuroradiology. 2000;42:629–33.PubMed

Hornig CR, Bauer T, Simon C, Trittmacher S, Dorndorf W. Hemorrhagic transformation in cardioembolic cerebral infarction. Stroke. 1993;24:465–68.PubMed

Okada Y, Yamaguchi T, Minematsu K, et al. Hemorrhagic transformation in cerebral embolism. Stroke. 1989;20:598–603.PubMed

Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group Alberta Stroke Programme Early CT Score Lancet. 2000;355:1670–74.

Dzialowski I, Hill M, Coutts S, et al. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke. 2006;37:973–78.PubMed

10.

Puetz V, Dzialowski I, Hill MD, et al. Intracranial thrombus extent predicts clinical outcome, final infarct size and hemorrhagic transformation in ischemic stroke: the clot burden score. Int J Stroke. 2008;3:230–36.PubMed

11.

Sakamoto Y, Kimura K, Iguchi Y, Shibazaki K, Aoki J. Hemorrhagic transformation in acute cerebellar infarction. Cerebrovasc Dis. 2011;32:327–33.PubMed

12.

Singer O, Kurre W, Humpich M, et al. Risk assessment of symptomatic intracerebral hemorrhage after thrombolysis using DWI-ASPECTS. Stroke. 2009;40:2743–48.PubMed

13.

Selim M, Fink J, Kumar S, et al. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke. 2002;33:2047–52.PubMed

14.

Vo K, Santiago F, Lin W, Hsu C, Lee Y, Lee J. MR imaging enhancement patterns as predictors of hemorrhagic transformation in acute ischemic stroke. AJNR. 2003;24:674–79.PubMed

15.

Kim EY, Na DG, Kim SS, Lee KH, Ryoo JW, Kim HK. Prediction of hemorrhagic transformation in acute ischemic stroke: role of diffusion-weighted imaging and early parenchymal enhancement. AJNR. 2005;26:1050–55.PubMed

16.

Latour L, Kang D, Ezzeddine M, Chalela J, Warach S. Early blood–brain barrier disruption in human focal brain ischemia. Ann Neurol. 2004;56:468–47.PubMed

17.

Cho A, Kim J, Kim S, et al. Focal fluid-attenuated inversion recovery hyperintensity within acute diffusion-weighted imaging lesions is associated with symptomatic intracerebral hemorrhage after thrombolysis. Stroke. 2008;39:3424–26.PubMed

18.

Kim EY, Kim SS, Na DG, Roh HG, Ryoo JW, Kim HK. Sulcal hyperintensity on fluid-attenuated inversion recovery imaging in acute ischemic stroke patients treated with intra-arterial thrombolysis: iodinated contrast media as its possible cause and the association with hemorrhagic transformation. J Comput Assist Tomogr. 2005;29:264–69.PubMed

19.

Campbell BC, Costello C, Christensen S, et al. Fluid-attenuated inversion recovery hyperintensity in acute ischemic stroke may not predict hemorrhagic transformation. Cerebrovasc Dis. 2011;32:401–45.PubMed

20.

Kassner A, Roberts T, Taylor K, Silver F, Mikulis D. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. AJNR. 2005;26:2213–17.PubMed

21.

Thornhill RE, Chen S, Rammo W, Mikulis DJ, Kassner A. Contrast-enhanced MR imaging in acute ischemic stroke: T2* measures of blood–brain barrier permeability and their relationship to T1 estimates and hemorrhagic transformation. AJNR. 2010;31:1015–22.PubMed

22.

Bang O, Saver J, Alger J, et al. Patterns and predictors of blood–brain barrier permeability derangements in acute ischemic stroke. Stroke. 2009;40:454–61.PubMed

23.

Kim JH, Bang OY, Liebeskind DS, et al. Impact of baseline tissue status (diffusion-weighted imaging lesion) versus perfusion status (severity of hypoperfusion) on hemorrhagic transformation. Stroke. 2010;41:e135–42.PubMed

24.

Albers G, Thijs V, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60:508–17.PubMed

25.

Kakuda W, Hamilton S, Thijs V, et al. Optimal outcome measures for detecting clinical benefits of early reperfusion: insights from the DEFUSE Study. J Stroke Cerebrovasc Dis. 2008;17:235–40.PubMed

26.

Davis S, Donnan G, Parsons M, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299–309.PubMed

27.

Schaefer P, Barak E, Kamalian S, et al. Quantitative assessment of core/penumbra mismatch in acute stroke: CT and MR perfusion imaging are strongly correlated when sufficient brain volume is imaged. Stroke. 2008;39:2986–92.PubMed

28.

Souza LC, Payabvash S, Wang Y, et al. Admission CT perfusion is an independent predictor of hemorrhagic transformation in acute stroke with similar accuracy to DWI. Cerebrovasc Dis. 2012;33:8–15.PubMed

29.

Inoue M, Mlynash M, Straka M, et al. Patients with the malignant profile within 3 hours of symptom onset have very poor outcomes after intravenous tissue-type plasminogen activator therapy. Stroke. 2012;43:2494–26.PubMed

30.

Aviv R, d'Esterre C, Murphy B, et al. Hemorrhagic transformation of ischemic stroke: prediction with CT perfusion. Radiology. 2009;250:867–77.PubMed

31.

Hom J, Dankbaar JW, Soares BP, et al. Blood–brain barrier permeability assessed by perfusion CT predicts symptomatic hemorrhagic transformation and malignant edema in acute ischemic stroke. AJNR. 2011;32:41–8.PubMed

32.

Garcia-Bermejo P, Calleja A, Perez-Fernandez S, et al. Perfusion computed tomography-guided intravenous thrombolysis for acute ischemic stroke beyond 4.5 hours: a case–control study. Cerebrovasc Dis. 2012;34:31–7.PubMed

33.

Kidwell C, Saver J, Villablanca JP, et al. Magnetic resonance imaging detection of microbleeds before thrombolysis: an emerging application. Stroke. 2002;33:95–8.PubMed

34.

Kim B, Lee S. Silent microbleeds and hemorrhagic conversion of an embolic infarction. J Clin Neurol. 2007;3:147–49.PubMed

35.

Koennecke H. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications. Neurology. 2006;66:165–71.PubMed

36.

Derex L, Nighoghossian N, Hermier M, et al. Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis. 2004;17:238–41.PubMed

37.

Fiehler J, Albers G, Boulanger J, et al. Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke. 2007;38:2738–44.PubMed

38.

Hermier M, Nighoghossian N, Derex L, et al. Hypointense transcerebral veins at T2*-weighted MRI: a marker of hemorrhagic transformation risk in patients treated with intravenous tissue plasminogen activator. J Cereb Blood Flow Metab. 2003;23:1362–70.PubMed

39.

Patt A, Horesh IR, Berger EM, Harken AH, Repine JE. Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains. J Pediatr Surg. 1990;25:224–7.PubMed

40.

Erdemoglu AK, Ozbakir S. Serum ferritin levels and early prognosis of stroke. Euro J Neurol. 2002;9:633–37.

41.••

Choi K, Park M, Kim J, Nam T, Cho K. The serum ferritin level is an important predictor of hemorrhagic transformation in acute ischaemic stroke. Euro J Neurol. 2012;19:570–7. This current study is instrumental for assessing ferritin as a clinical predictor of HT.

42.

Herbert V, Jayatilleke E, Shaw S, et al. Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells. 1997;15:291–26.PubMed

43.

Sindic CJ, Collet Cassart D, Cambiaso CL, Masson PL. The clinical relevance of ferritin concentration in the cerebrospinal fluid. J Neurol Neurosurg Psychiatry. 1981;44:329–33.PubMed

44.

Fehling C, Qvist I. Ferritin concentration in cerebrospinal fluid. Acta Neurol Scand. 1985;71:510–12.PubMed

45.

Millan M, Sobrino T, Castellanos M, et al. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke. Stroke. 2007;38:90–5.PubMed

46.

Ribo M, Montaner J, Molina C, et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke. 2004;35:2123–27.PubMed

47.

Hajat C, Hajat S, Sharma P. Effects of poststroke pyrexia on stroke outcome: a meta-analysis of studies in patients. Stroke. 2000;31:410–14.PubMed

48.

Greer D, Funk S, Reaven N, Ouzounelli M, Uman G. Impact of fever on outcome in patients with stroke and neurologic injury: a comprehensive meta-analysis. Stroke. 2008;39:3029–35.PubMed

49.••

Leira R, Sobrino T, Blanco M, et al. A higher body temperature is associated with haemorrhagic transformation in patients with acute stroke untreated with recombinant tissue-type plasminogen activator (rtPA). Clin Sci. 2012;122:113–19. This study provides evidence for the management of body temperature in the HT patient.PubMed

50.

Millán M, Grau L, Castellanos M, et al. Body temperature and response to thrombolytic therapy in acute ischaemic stroke. Euro J Neurol. 2008;15:1384–89.

51.

Dixon S, Whitbourn R, Dae M, et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol. 2002;40:1928–34.PubMed

52.

Chen J, Ji X, Ding Y, Luo Y, Cheng H, Ling F. A novel approach to reduce hemorrhagic transformation after interventional management of acute stroke: catheter-based selective hypothermia. Med Hypotheses. 2009;72:62–3.PubMed

53.

Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 1997;28:2109–18.

54.

Bravo Y, Martí-Fàbregas J, Cocho D, et al. Influence of antiplatelet pre-treatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis. Cerebrovasc Dis. 2008;26:126–33.PubMed

55.

Sobesky J, Frackowiak M, Zaro Weber O, et al. The Cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis. Cerebrovasc Dis. 2007;24:56–65.PubMed

56.

Schmalling S, Rudolf J, Strotmann Tack T, et al. Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis. 2003;16:183–90.

57.

Tanne D, Kasner S, Demchuk A, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002;105:1679–85.PubMed

58.

Larrue V. Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Secondary Analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32:438–41.PubMed

59.

Uyttenboogaart M, Koch M, Koopman K, Vroomen PCAJ, De Keyser J, Luijckx G. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol. 2008;65:607–11.PubMed

60.

Cucchiara B, Kasner S, Tanne D, et al. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials. Stroke. 2009;40:3067–72.PubMed

61.

Mazya M, Egido J, Ford G, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012;43:1524–31.PubMed

62.

Diener H, Bogousslavsky J, Brass L, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331–37.PubMed

63.

Hermann A, Dzialowski I, Koch R, Gahn G. Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke? J Neurol Sci. 2009;284:155–57.PubMed

64.

Diedler J, Ahmed N, Sykora M, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke. 2010;41:288–94.PubMed

65.

Adams H, del Zoppo G, Alberts M, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655–711.PubMed

66.

Brott T, Lu M, Kothari R, et al. Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke. 1998;29:1504–09.PubMed

67.

Jaillard A, Cornu C, Durieux A, et al. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. Stroke. 1999;30:1326–32.PubMed

68.

Wahlgren N, Ahmed N, Eriksson N, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke. 2008;39:3316–22.PubMed

69.

Hill M, Buchan A. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005;172:1307–12.PubMed

70.

Dawson SL, Blake MJ, Panerai RB, Potter JF. Dynamic but not static cerebral autoregulation is impaired in acute ischaemic stroke. Cerebrovasc Dis. 2000;10:126–32.PubMed

71.

Dawson SL, Blake MJ, Panerai RB, Potter JF. Dynamic but not static cerebral autoregulation is impaired in acute ischaemic stroke. Cerebrovasc Dis. 2000;10:126–32.PubMed

72.

Yong M, Kaste M. Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial. Stroke. 2008;39:366–72.PubMed

73.

Delgado Mederos R, Ribo M, Rovira A, et al. Prognostic significance of blood pressure variability after thrombolysis in acute stroke. Neurology. 2008;71:552–58.PubMed

74.

Butcher K, Christensen S, Parsons M, et al. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation. Stroke. 2010;41:72–7.PubMed

75.

Butcher K, Christensen S, Parsons M, et al. Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation. Stroke. 2010;41:72–7.PubMed

76.••

Ko Y, Park J, Yang M, et al. The significance of blood pressure variability for the development of hemorrhagic transformation in acute ischemic stroke. Stroke. 2010;41:2512–18. In this study, variability of blood pressure was reported as a clinical predictor of HT.PubMed

77.

Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318–22.PubMed

78.

Awad IA, Spetzler RF, Hodak JA, Awad CA, Carey R. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. I Correlation with age and cerebrovascular risk factors Stroke. 1986;17:1084–89.

79.

Biffi A, Greenberg S. Cerebral amyloid angiopathy: a systematic review. J Clin Neurol. 2011;7:1–9.PubMed

80.

Ariës MJH, Uyttenboogaart M, Vroomen PC, De Keyser J, Luijckx GJ. tPA treatment for acute ischaemic stroke in patients with leukoaraiosis. Euro J Neurol. 2010;17:866–70.

81.

Neumann Haefelin T, Hoelig S, Berkefeld J, et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke. 2006;37:2463–66.PubMed

82.

Sloan MA, Price TR, Petito CK, et al. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. Neurology. 1995;45:649–58.PubMed

83.

Gebel JM, Sila CA, Sloan MA, et al. Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Stroke. 1998;29:563–69.

84.

Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–74.PubMed

85.

Sylaja PN, Cote R, Buchan A, Hill M. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry. 2006;77:826–29.PubMed

86.

Ford G, Ahmed N, Azevedo E, et al. Intravenous alteplase for stroke in those older than 80 years old. Stroke. 2010;41:2568–74.PubMed

87.••

Cronin C, Shah N, Morovati T, Hermann L, Sheth K. No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study (ECASS) exclusion criteria. Stroke. 2012;43:1684–86. Results of this study question the current age parameters for the extended window exclusion criteria.PubMed

88.

Pundik S, McWilliams Dunnigan L, Blackham K, et al. Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke. J Stroke Cerebrovasc Dis. 2008;17:266–72.PubMed

89.

Costello CA, Campbell BCV. Perez de la Ossa N, et al. Age over 80 years is not associated with increased hemorrhagic transformation after stroke thrombolysis. J Clin Neurosci. 2012;19:360–63.PubMed

90.

Garcia Caldentey J, Alonso de Lecia AM, Simal P, et al. Intravenous thrombolytic treatment in the oldest old. Stroke Res Treat. 2012;2012:923676.PubMed

91.

Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002;59:669–74.PubMed

92.

Bruno A, Biller J, Adams HP, et al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology. 1999;52:280–84.PubMed

93.

94.

Yong M, Kaste M. Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke. 2008;39:2749–55.PubMed

95.

Thomalla G, Sobesky J, Köhrmann M, et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke. 2007;38:313–18.PubMed

96.

Baird T, Parsons M, Phanh T, et al. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke. 2003;34:2208–14.PubMed

97.

Ahmed N, Dávalos A, Eriksson N, et al. Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol. 2010;67:1123–30.PubMed

98.

Poppe A, Majumdar S, Jeerakathil T, Ghali W, Buchan A, Hill M. Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Diabetes Care. 2009;32:617–22.PubMed

99.

Kent TA, Soukup VM, Fabian RH. Heterogeneity affecting outcome from acute stroke therapy: making reperfusion worse. Stroke. 2001;32:2318–27.PubMed

100.

Kawai N, Keep RF, Betz AL. Hyperglycemia and the vascular effects of cerebral ischemia. Acta Neurochirurgica Supplementum. 1997;70:27–9.

101.

Kawagishi T, Matsuyoshi M, Emoto M, et al. Impaired endothelium-dependent vascular responses of retinal and intrarenal arteries in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol. 1999;19:2509–16.PubMed

102.

Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest. 1994;94:110–7.PubMed

103.

Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001;32:2426–32.PubMed

104.

Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI. Insulin resistance and risk for stroke. Neurology. 2002;59:809–15.PubMed

105.

Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ. 1997;314:1303–06.PubMed

106.

Allport L, Butcher K, Baird T, et al. Insular cortical ischemia is independently associated with acute stress hyperglycemia. Stroke. 2004;35:1886–91.PubMed

107.

Dietrich WD, Alonso O, Busto R. Moderate hyperglycemia worsens acute blood–brain barrier injury after forebrain ischemia in rats. Stroke. 1993;24:111–6.PubMed

108.

Won S, Tang X, Suh S, Yenari M, Swanson R. Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production. Ann Neurol. 2011;70:583–90.PubMed

109.

Tang J, Liu J, Zhou C, et al. Role of NADPH oxidase in the brain injury of intracerebral hemorrhage. J Neurochem. 2005;94:1342–50.PubMed

110.

Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem. 1994;269:9889–97.PubMed

111.

Siemkowicz E, Hansen AJ. Clinical restitution following cerebral ischemia in hypo-, normo- and hyperglycemic rats. Acta Neurol Scand. 1978;58:1–8.PubMed

112.

Gisselsson L, Smith ML, Siesjö BK. Hyperglycemia and focal brain ischemia. J Cereb Blood Flow Metab. 1999;19:288–97.PubMed

113.

Gray C, Hildreth A, Sandercock P, et al. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol. 2007;6:397–406.PubMed

114.••

Southerland A, Johnston K. Considering hyperglycemia and thrombolysis in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial. Ann N Y Acad Sci. 2012;1268:72–8. Results of this study are pending and can influence current management of the HT patient.PubMed

115.

Lapchak P. Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep. 2002;2:38–43.PubMed

116.

Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31:3034–40.PubMed

117.

Facchinetti F, Dawson VL, Dawson TM. Free radicals as mediators of neuronal injury. Cell Mol Neurobiol. 1998;18:667–82.PubMed

118.

Peeling J, Yan HJ, Chen SG, Campbell M, Del Bigio MR. Protective effects of free radical inhibitors in intracerebral hemorrhage in rat. Brain Res. 1998;795:63–70.PubMed

119.

Asahi M, Asahi K, Wang X, Lo EH. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2000;20:452–57.PubMed

120.

Schulz JB, Panahian N, Chen YI, et al. Facilitation of postischemic reperfusion with alpha-PBN: assessment using NMR and Doppler flow techniques. Am J Physiol. 1997;272:H1986–H95.PubMed

121.

Rosenberg GA. Matrix metalloproteinases in brain injury. J Neurotrauma. 1995;12:833–42.PubMed

122.

Gearing AJ, Beckett P, Christodoulou M, et al. Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukoc Biol. 1995;57:774–77.PubMed

123.

Wang X, Tsuji K, Lee S, et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke. 2004;35:2726–30.PubMed

124.

Fujimura M, Gasche Y, Morita Fujimura Y, Massengale J, Kawase M, Chan PH. Early appearance of activated matrix metalloproteinase-9 and blood–brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 1999;842:92–100.PubMed

125.

Lo E, Wang X, Cuzner ML. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res. 2002;69:1–9.PubMed

126.

Cuadrado E, Rosell A, Penalba A, et al. Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. J Proteome Res. 2009;8:3191–97.PubMed

127.

Tsuji K, Aoki T, Tejima E, et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke. 2005;36:1954–59.PubMed

128.

Copin J, Bengualid D, Da Silva R, Kargiotis O, Schaller K, Gasche Y. Recombinant tissue plasminogen activator induces blood–brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse. Eur J Neurosci. 2011;34:1085–92.PubMed

129.

Lukes A, Mun Bryce S, Lukes M, Rosenberg GA. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol. 1999;19:267–84.PubMed

130.

Sood R, Taheri S, Candelario Jalil E, Estrada E, Rosenberg G. Early beneficial effect of matrix metalloproteinase inhibition on blood–brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J Cereb Blood Flow Metab. 2008;28:431–38.PubMed

131.

Yamashita T, Kamiya T, Deguchi K, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab. 2009;29:715–25.PubMed

132.

Zhang W, Sato K, Hayashi T, et al. Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain. Neurol Res. 2004;26:342–48.PubMed

133.

Simard JM, Woo S, Tsymbalyuk N, et al. Glibenclamide-10-h Treatment Window in a Clinically Relevant Model of Stroke. Transl Stroke Res. 2012;3:286–95.PubMed

134.

Kunte H, Schmidt S, Eliasziw M, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke. 2007;38:2526–30.PubMed

135.••

Simard JM, Geng Z, Silver F, et al. Does inhibiting Sur1 complement rt-PA in cerebral ischemia? Ann N Y Acad Sci. 2012;1268:95–107. In this retrospective study, the role of sulfonylureas on the development of HT was demonstrated. Results of the currently recruiting GAMES study may impact future management of the HT patient.PubMed

136.

Lou M, Safdar A, Mehdiratta M, et al. The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology. 2008;71:1417–23.PubMed

137.

Tsivgoulis G, Saqqur M, Barreto A, et al. Validity of HAT score for predicting symptomatic intracranial hemorrhage in acute stroke patients with proximal occlusions: data from randomized trials of sonothrombolysis. Cerebrovasc Dis. 2011;31:471–76.PubMed

138.

Cucchiara B, Tanne D, Levine S, Demchuk A, Kasner S. A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke. J Stroke Cerebrovasc Dis. 2008;17:331–33.PubMed

139.

Cucchiara B, Kasner S, Tanne D, et al. Validation assessment of risk scores to predict postthrombolysis intracerebral haemorrhage. Int J Stroke. 2011;6:109–11.PubMed

140.

Menon B, Saver J, Prabhakaran S, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke. 2012;43:2293–99.PubMed

141.

142.

Saposnik, Fang, Kapral, et al. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke. 2012;43:1315–22.

143.

Seidel G, Cangr H, Albers T, Burgemeister A, Meyer Wiethe K. Sonographic evaluation of hemorrhagic transformation and arterial recanalization in acute hemispheric ischemic stroke. Stroke. 2009;40:119–23.PubMed

144.

Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007;38:2001–23.PubMed

145.

Diringer M. Treatment of fever in the neurologic intensive care unit with a catheter-based heat exchange system. Crit Care Med. 2004;32:559–64.PubMed

Titel: Clinical Predictors and Management of Hemorrhagic Transformation
verfasst von: Raphaella E. Weiser, MD
Kevin N. Sheth, MD, FAHA
Publikationsdatum: 01.04.2013
Verlag: Current Science Inc.
Erschienen in: Current Treatment Options in Neurology / Ausgabe 2/2013
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-012-0217-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Clinical Predictors and Management of Hemorrhagic Transformation

Opinion statement

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Opinion statement

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Paraneoplastic Syndromes of the Neuromuscular Junction: Therapeutic Options in Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, and Neuromyotonia

Treatment of Paraneoplastic Cerebellar Degeneration

Limbic Encephalitis and Related Cortical Syndromes

Sonothrombolysis in Ischemic Stroke

Paraneoplastic Brain Stem Encephalitis

Paraneoplastic Neurological Syndromes: General Treatment Overview

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie